We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
AYTU BioPharma Inc | NASDAQ:AYTU | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.01 | 2.94 | 3.14 | 3.04 | 2.92 | 2.96 | 21,150 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐
Check the appropriate box:
☐ |
Preliminary Proxy Statement |
|||||||
☐ |
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|||||||
☐ |
Definitive Proxy Statement |
|||||||
☒ |
Definitive Additional Materials |
|||||||
☐ |
Soliciting Material Pursuant to § 240.14a-12 |
Aytu BioPharma, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
☒ |
No fee required. |
|||||||||||||
☐ |
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. |
|||||||||||||
(1) |
Title of each class of securities to which transaction applies: |
|||||||||||||
(2) |
Aggregate number of securities to which transaction applies: |
|||||||||||||
AYTU BIOPHARMA, INC.
373 Inverness Parkway, Suite 206
Englewood, Colorado 80112
May 20, 2021
Dear Aytu Stockholder:
The proxy statement of the 2021 Annual Meeting of the Stockholders (the “Proxy Statement”) of Aytu BioPharma, Inc., a Delaware corporation (the “Company”), to be held on May 21, 2021 (the “Meeting”), was filed with the Securities and Exchange Commission on April 19, 2021. Since then, there have been developments regarding the Board of Directors of the Company (the “Board”). This communication describes these recent events and supplements portions of the Proxy Statement as set forth in this supplement to the Proxy Statement.
Recent Developments
On May 17, 2021, the Board accepted the resignations of Beth Hecht and Gerald McLaughlin from the Board, effective as of May 17, 2021.
Impact on Voting at the Meeting
Stockholders do not need to take any action if they have already voted their shares for the Meeting. Any votes cast for Beth Hecht and Gerald McLaughlin will be disregarded and not counted. It is not necessary for you to re-vote your shares if you have already voted or obtain a new proxy card if you have not yet voted. Any stockholder of record who wants to re-vote or change a previously executed proxy may do so by following the instructions set forth in the Proxy Statement.
Thank you for your ongoing support of and continued interest in Aytu BioPharma, Inc.
Sincerely, /s/ Joshua Disbrow Joshua R. Disbrow Chairman and Chief Executive Officer |
||
1 Year AYTU BioPharma Chart |
1 Month AYTU BioPharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions